Top Markets
Coin of the day
Orchard Therapeutics plc Orchard Therapeutics plc

Orchard Therapeutics plc

ORTX
Rang in aandelen #18160
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing... Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Aandeelprijs
$16.70
Laatst gesynchroniseerd: 2024-02-02
Marktkapitalisatie
$210.34M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
GB
Handel Orchard Therapeutics plc (ORTX)

Categorie

P/S-ratio voor Orchard Therapeutics plc (ORTX)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Orchard Therapeutics plc is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Orchard Therapeutics plc van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH